Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS)
Objectives - New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health technology and cost-effectiveness assessments can be limited. We estimated the bur...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
8 June 2018
|
| In: |
Lung cancer
Year: 2018, Jahrgang: 124, Pages: 298-309 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2018.06.007 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2018.06.007 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500218304161 
|
| Verfasserangaben: | Stefan Andreas, Christos Chouaid, Sarah Danson, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Mark Price, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1698763638 | ||
| 003 | DE-627 | ||
| 005 | 20230427091736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200525s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2018.06.007 |2 doi | |
| 035 | |a (DE-627)1698763638 | ||
| 035 | |a (DE-599)KXP1698763638 | ||
| 035 | |a (OCoLC)1341326289 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Andreas, Stefan |d 1961- |e VerfasserIn |0 (DE-588)1160883459 |0 (DE-627)102428011X |0 (DE-576)50621740X |4 aut | |
| 245 | 1 | 0 | |a Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom |b a retrospective observational study (LuCaBIS) |c Stefan Andreas, Christos Chouaid, Sarah Danson, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Mark Price, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis |
| 264 | 1 | |c 8 June 2018 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.05.2020 | ||
| 520 | |a Objectives - New adjuvant treatments are being developed for patients with resected non-small cell lung cancer (NSCLC). Due to scarcity of real-world data available for treatment costs and resource utilization, health technology and cost-effectiveness assessments can be limited. We estimated the burden and cost-of-illness associated with completely resected stage IB-IIIA NSCLC in France, Germany and the United Kingdom (UK). - Materials and methods - Eligible patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC between August 2009 and July 2012. Patients (living or deceased) were enrolled at clinical sites by a systematic sampling method. Data were obtained from medical records and patient surveys. Direct, indirect and patient out-of-pocket expenses were estimated by multiplying resource use by country-specific unit costs. National annual costs were estimated based on disease prevalence data available from published sources. - Results - 39 centers provided data from 831 patients of whom patient surveys were evaluable in 306 patients. Median follow-up was 26 months. The mean total direct costs per patient during follow-up were: €19,057 (France), €14,185 (Germany), and €8377 (UK). The largest cost drivers were associated with therapies received (€12,375 France; €3694 UK), and hospitalization/emergency costs (€7706 Germany). Monthly direct costs per patient were the highest during the distant metastasis/terminal illness phase in France (€15,562) and Germany (€6047) and during the adjuvant treatment period in the UK (€2790). Estimated mean total indirect costs per patient were: €696 (France), €2476 (Germany), and €1414 (UK). Estimates for the annual national direct cost were €478.4 million (France), €574.6 million (Germany) and €325.8 million (UK). - Conclusion - To our knowledge, this is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC. The economic burden was substantial in all three countries. Treatment of NSCLC is associated with large annual national costs, mainly incurred during disease progression. | ||
| 650 | 4 | |a Adjuvant therapy | |
| 650 | 4 | |a Cost of adverse event | |
| 650 | 4 | |a Direct cost | |
| 650 | 4 | |a Economic burden | |
| 650 | 4 | |a Indirect cost | |
| 650 | 4 | |a Non-small cell lung cancer (NSCLC) | |
| 700 | 1 | |a Chouaid, Christos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Danson, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siakpere, Obukohwo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benjamin, Laure |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ehness, Rainer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dramard-Goasdoue, Marie-Hélène |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barth, Janina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, Hans |d 1957- |e VerfasserIn |0 (DE-588)1022900455 |0 (DE-627)71732852X |0 (DE-576)366147730 |4 aut | |
| 700 | 1 | |a Potter, Vanessa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barlesi, Fabrice |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chirila, Costel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hollis, Kelly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sweeney, Carolyn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Price, Mark |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolowacz, Sorrel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaye, James A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kontoudis, Ilias |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 124(2018), Seite 298-309 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom a retrospective observational study (LuCaBIS) |
| 773 | 1 | 8 | |g volume:124 |g year:2018 |g pages:298-309 |g extent:12 |a Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom a retrospective observational study (LuCaBIS) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2018.06.007 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500218304161 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200525 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1022900455 |a Hoffmann, Hans |m 1022900455:Hoffmann, Hans |d 50000 |e 50000PH1022900455 |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1698763638 |e 3670764518 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1698763638","id":{"doi":["10.1016/j.lungcan.2018.06.007"],"eki":["1698763638"]},"name":{"displayForm":["Stefan Andreas, Christos Chouaid, Sarah Danson, Obukohwo Siakpere, Laure Benjamin, Rainer Ehness, Marie-Hélène Dramard-Goasdoue, Janina Barth, Hans Hoffmann, Vanessa Potter, Fabrice Barlesi, Costel Chirila, Kelly Hollis, Carolyn Sweeney, Mark Price, Sorrel Wolowacz, James A. Kaye, Ilias Kontoudis"]},"person":[{"family":"Andreas","display":"Andreas, Stefan","roleDisplay":"VerfasserIn","given":"Stefan","role":"aut"},{"given":"Christos","roleDisplay":"VerfasserIn","display":"Chouaid, Christos","family":"Chouaid","role":"aut"},{"role":"aut","family":"Danson","roleDisplay":"VerfasserIn","display":"Danson, Sarah","given":"Sarah"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Siakpere, Obukohwo","given":"Obukohwo","family":"Siakpere"},{"role":"aut","display":"Benjamin, Laure","roleDisplay":"VerfasserIn","given":"Laure","family":"Benjamin"},{"roleDisplay":"VerfasserIn","display":"Ehness, Rainer","given":"Rainer","family":"Ehness","role":"aut"},{"given":"Marie-Hélène","roleDisplay":"VerfasserIn","display":"Dramard-Goasdoue, Marie-Hélène","family":"Dramard-Goasdoue","role":"aut"},{"role":"aut","display":"Barth, Janina","roleDisplay":"VerfasserIn","given":"Janina","family":"Barth"},{"role":"aut","family":"Hoffmann","roleDisplay":"VerfasserIn","display":"Hoffmann, Hans","given":"Hans"},{"display":"Potter, Vanessa","roleDisplay":"VerfasserIn","given":"Vanessa","family":"Potter","role":"aut"},{"role":"aut","display":"Barlesi, Fabrice","roleDisplay":"VerfasserIn","given":"Fabrice","family":"Barlesi"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Costel","display":"Chirila, Costel","family":"Chirila"},{"family":"Hollis","given":"Kelly","roleDisplay":"VerfasserIn","display":"Hollis, Kelly","role":"aut"},{"role":"aut","family":"Sweeney","display":"Sweeney, Carolyn","roleDisplay":"VerfasserIn","given":"Carolyn"},{"family":"Price","display":"Price, Mark","roleDisplay":"VerfasserIn","given":"Mark","role":"aut"},{"family":"Wolowacz","roleDisplay":"VerfasserIn","display":"Wolowacz, Sorrel","given":"Sorrel","role":"aut"},{"role":"aut","given":"James A.","roleDisplay":"VerfasserIn","display":"Kaye, James A.","family":"Kaye"},{"family":"Kontoudis","given":"Ilias","roleDisplay":"VerfasserIn","display":"Kontoudis, Ilias","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom","subtitle":"a retrospective observational study (LuCaBIS)","title_sort":"Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"8 June 2018"}],"note":["Gesehen am 25.05.2020"],"relHost":[{"id":{"zdb":["2025812-4"],"eki":["320649733"],"issn":["1872-8332"]},"recId":"320649733","origin":[{"dateIssuedKey":"1985","publisher":"Elsevier","dateIssuedDisp":"1985-","publisherPlace":"Amsterdam [u.a.]"}],"pubHistory":["1.1985 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 20.02.20"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"124","text":"124(2018), Seite 298-309","extent":"12","year":"2018","pages":"298-309"},"disp":"Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom a retrospective observational study (LuCaBIS)Lung cancer","language":["eng"],"title":[{"title_sort":"Lung cancer","title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}]}],"physDesc":[{"extent":"12 S."}],"language":["eng"]} | ||
| SRT | |a ANDREASSTEECONOMICBU8201 | ||